Potential role of various dosimetric quality indicators in prostate brachytherapy.

[1]  W. Butler,et al.  Isotope choice and the effect of edema on prostate brachytherapy dosimetry. , 2000, Medical physics.

[2]  W. Butler,et al.  Rectal dosimetric analysis following prostate brachytherapy. , 1999, International journal of radiation oncology, biology, physics.

[3]  G S Merrick,et al.  Quality assurance calibration of 125I rapid strand in a sterile environment. , 1998, International journal of radiation oncology, biology, physics.

[4]  R. Stock,et al.  A dose-response study for I-125 prostate implants. , 1998, International journal of radiation oncology, biology, physics.

[5]  J J Prete,et al.  Timing of computed tomography-based postimplant assessment following permanent transperineal prostate brachytherapy. , 1998, International journal of radiation oncology, biology, physics.

[6]  N. Yue,et al.  Edema associated with I-125 or Pd-103 prostate brachytherapy and its impact on post-implant dosimetry: an analysis based on serial CT acquisition. , 1998, International Journal of Radiation Oncology, Biology, Physics.

[7]  W. Butler,et al.  Influence of timing on the dosimetric analysis of transperineal ultrasound-guided, prostatic conformal brachytherapy. , 1998, Radiation oncology investigations.

[8]  F. Shamsa,et al.  Regarding, Dattoli, Wallner, Sorace, Koval, Cash, Acosta, Brown, Etheridge, Binder, Brunelle, Kirwan, Sanchez, Stein, and Wasserman IJROBP 35(5):875-879; 1996. , 1997, International journal of radiation oncology, biology, physics.

[9]  K. Wallner,et al.  CT-based dosimetry for transperineal I-125 prostate brachytherapy. , 1997, International journal of radiation oncology, biology, physics.

[10]  J. Blasko,et al.  Interstitial iodine‐125 radiation without adjuvant therapy in the treatment of clinically localized prostate carcinoma , 1997, Cancer.

[11]  B W Corn,et al.  Effect of edema on the post-implant dosimetry of an I-125 prostate implant: a case study. , 1997, International journal of radiation oncology, biology, physics.

[12]  W. H. Williams,et al.  Prostate-specific antigen nadir of 0.5 ng/mL or less defines disease freedom for surgically staged men irradiated for prostate cancer. , 1997, Urology.

[13]  M A Moerland,et al.  Evaluation of permanent I-125 prostate implants using radiography and magnetic resonance imaging. , 1997, International journal of radiation oncology, biology, physics.

[14]  S. Stokes,et al.  Transperineal ultrasound-guided radioactive seed implantation for organ-confined carcinoma of the prostate. , 1997, International journal of radiation oncology, biology, physics.

[15]  1010 Source localization using magnetic resonance imaging following permanent transperineal interstitial prostate brachytherapy , 1997 .

[16]  R. Stock,et al.  1012 Dose response for iodine - 125 prostate implants , 1997 .

[17]  T. Buchholz,et al.  2097 A dose-volume analysis of permanent transperineal prostate brachytherapy , 1997 .

[18]  A. P. James,et al.  1045 Clinical and technical considerations for head and neck cancers treated by IMRT: Initial experience , 1997 .

[19]  K. Wallner,et al.  1011 Palladium-103 brachytherapy for clinical prostate carcinomas , 1997 .

[20]  A. K. Levinson,et al.  Prostate-specific antigen nadir: the optimum level after irradiation for prostate cancer. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  K. Wallner,et al.  103Pd brachytherapy and external beam irradiation for clinically localized, high-risk prostatic carcinoma. , 1996, International journal of radiation oncology, biology, physics.

[22]  P. Unger,et al.  Prostate specific antigen findings and biopsy results following interactive ultrasound guided transperineal brachytherapy for early stage prostate carcinoma , 1996, Cancer.

[23]  J Roy,et al.  Tumor control and morbidity following transperineal iodine 125 implantation for stage T1/T2 prostatic carcinoma. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  F M Waterman,et al.  Limitations of the minimum peripheral dose as a parameter for dose specification in permanent 125I prostate implants. , 1996, International journal of radiation oncology, biology, physics.

[25]  J. Blasko,et al.  79 Long-term outcomes of external beam irradiation and I-125/Pd-103 brachytherapy boost for prostate cancer , 1996 .

[26]  J. Blasko,et al.  Prostate specific antigen based disease control following ultrasound guided 125iodine implantation for stage T1/T2 prostatic carcinoma. , 1995, The Journal of urology.

[27]  J. Roy,et al.  Dosimetry guidelines to minimize urethral and rectal morbidity following transperineal I-125 prostate brachytherapy. , 1995, International journal of radiation oncology, biology, physics.

[28]  L. Anderson,et al.  Dosimetry of interstitial brachytherapy sources: Recommendations of the AAPM Radiation Therapy Committee Task Group No. 43 , 1995 .

[29]  J. Roy,et al.  Short-term freedom from disease progression after I-125 prostate implantation. , 1994, International journal of radiation oncology, biology, physics.

[30]  Blasko,et al.  Brachytherapy and Organ Preservation in the Management of Carcinoma of the Prostate. , 1993, Seminars in radiation oncology.

[31]  C C Ling,et al.  A CT-based evaluation method for permanent implants: application to prostate. , 1993, International journal of radiation oncology, biology, physics.

[32]  C. Ling.  Permanent implants using Au-198, Pd-103 and I-125: radiobiological considerations based on the linear quadratic model. , 1992, International journal of radiation oncology, biology, physics.

[33]  C B Begg,et al.  The effect of local control on metastatic dissemination in carcinoma of the prostate: long-term results in patients treated with 125I implantation. , 1991, International journal of radiation oncology, biology, physics.

[34]  C. Saw,et al.  Quantitative assessment of interstitial implants. , 1991, International journal of radiation oncology, biology, physics.

[35]  R. Peschel,et al.  Iodine-125 implants versus external beam therapy for stages A2, B, and C prostate cancer. , 1988, International journal of radiation oncology, biology, physics.